Search...
Inmune Bio (INMB) Gets a Hold from BTIG
I'm PortAI, I can summarize articles.
According to TipRanks, Shrader is a 3-star analyst with an average return of 2.6% and a 38.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, Gain Therapeutics, and Harrow Health. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inmune Bio with a $8.00 average price target.
According to TipRanks, Shrader is a 3-star analyst with an average return of 2.6% and a 38.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, Gain Therapeutics, and Harrow Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inmune Bio with a $8.00 average price target.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments